$TEM · Tempus AI, Inc.
Tempus AI filed an 8-K disclosing a Fifth Amendment to its Master Services Agreement with AstraZeneca, effective Jan 1, 2027. The amendment establishes a new five-year financial commitment period through Dec 31, 2031, with AstraZeneca committing $200M in aggregate fees ($40M annual target, $32M annual minimum). AstraZeneca retains the right to terminate for convenience but must pay any shortfall of the $200M commitment if it terminates before fulfilling it.
- AstraZeneca committed $200M in aggregate fees over the Renewal Term.
- Annual target spend is $40M; annual minimum is $32M per calendar year.
- Term extends through Dec 31, 2031, with possible extension to 2032 if commitment unmet.
- AstraZeneca retains termination-for-convenience rights but owes shortfall if it exits early.
- Amendment effective Jan 1, 2027, extending the original Nov 17, 2021 MSA.
Extended-hours last trade $63.99, +0.88% vs regular close but -1.19% vs price at filing; regular session down 2.05%. Modest positive reaction to a revenue-commitment extension.
A $200M committed revenue stream from a major pharma partner strengthens Tempus's multi-year revenue visibility.
Extends a multi-year strategic collaborator relationship in AI-driven precision medicine, reinforcing recurring revenue visibility for Tempus.
AstraZeneca can terminate for convenience at any time, though it would owe any shortfall of the $200M commitment.